A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).

NCT00946647 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

113

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndromes
Chronic Myelomonocytic Leukemia
Acute Myeloid Leukemia

Interventions

DRUG: Panobinostat (LBH589)
DRUG: 5-Azacytidine

Sponsor

Novartis Pharmaceuticals